Welcome to Natpar.com

This site is only for prescribing physicians outside the USA or UK who treat patients with hypoparathyroidism

Search Menu

Treatmentwith NATPAR

NATPAR is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.1

Dosing and titration to achieve the goals of treatment with NATPAR1

Clinical goal: To achieve calcaemic control and to reduce symptoms, while reducing calcium and reducing or discontinuing active vitamin D supplements.

iconos

Please refer to the SmPC for the full dosing and titration section

1. INITIATION

Before initiating NATPAR

  • Confirm 25-hydroxyvitamin D stores are sufficient
  • Confirm serum magnesium is within range
  • Measure serum calcium

Dose initiation table


*25 μg can be considered if serum calcium >2.25 mmol/L.

2-5 days

2. DOSE ADJUSTMENT

  • Measure pre-dose serum calcium (24 hours after the last injection). Repeat the following day, if it is below 1.87 mmol/L or above 2.55 mmol/L
  • Suggested adjustments to active vitamin D and calcium supplements are provided below based on serum calcium value and signs and symptoms of hypocalcaemia or hypercalcaemia

14-28 days

3. TITRATION

  • Further adjustment of NATPAR dose can be achieved by measuring post-dose serum calcium levels (8-12 hours after NATPAR injection) following the table below
  • Titration timeline is indicative and should be based on clinical assessment. Not all patients may require titration

Dose adjustment table

Image 7-reemplazada

† Downward titration can occur at any time. ‡Dose increments by 25 μg can occur every 2-4 weeks. Measurements of pre and post-dose serum calcium should be repeated and confirmed to be within an acceptable range before titration to a higher dose of NATPAR is considered.

Repeat until clinical goal is met

  • Pre-dose serum calcium is between 2.0-2.25 mmol/L
  • Active vitamin D has been discontinued
  • Calcium supplementation is sufficient to meet daily requirements

NATPAR instructions for use

Click here for full instructions for use

Full instructions on the preparation and injection of NATPAR are provided in the package leaflet. The following video is included as an example of a Takeda resource to support patients taking NATPAR

References

  1. NATPAR Summary of Product Characteristics.

Natpar® (parathyroid hormone (rDNA)


Detailed Safety Information

Please consult the Natpar Summary Product Characteristics (SmPC) before prescribing.

Natpar treatment should be supervised by a physician or other qualified healthcare professional experienced in the management of patients with hypoparathyroidism. The goal of treatment is to achieve calcaemic control and to reduce symptoms. The optimisation of parameters of calcium phosphate metabolism should be in line with current therapeutic guidelines for the treatment of hypoparathyroidism. Prior to initiating and during treatment with Natpar confirm that 25-OH vitamin D stores are sufficient and that serum magnesium is within the reference range.

Contraindications

Natpar is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, who are receiving or who have previously received radiation therapy to the skeleton, with skeletal malignancies or bone metastases, who are at increased baseline risk for osteosarcoma, with unexplained elevations of bone-specific alkaline phosphatase, with pseudohypoparathyroidism.

Warnings and Precautions

Monitoring of patients during treatment: pre-dose and in some cases post-dose serum calcium levels must be monitored during treatment with Natpar.

Hypercalcaemia: this was reported in clinical trials with Natpar. Hypercalcaemia commonly occurred during the titration period, during which doses of oral calcium, active vitamin D, and Natpar were being adjusted. Hypercalcaemia may be minimized by following the recommended dosing, the monitoring information and asking patients about any symptoms of hypercalcaemia. If severe hypercalcaemia develops, hydration and temporarily stopping Natpar, calcium and active vitamin D should be considered until serum calcium returns to the normal range. Then consider resuming Natpar, calcium and active vitamin D at lower doses.

Hypocalcaemia: a common clinical manifestation of hypoparathyroidism was reported in clinical trials with Natpar. Most of the hypocalcaemic events occurring in the clinical trials were mild to moderate severity. The risk for serious hypocalcaemia was greatest after the withdrawal of Natpar. Temporary or permanent discontinuation of Natpar must be accompanied by monitoring of serum calcium levels and increase of exogenous calcium and/or vitamin D sources as necessary. Hypocalcaemia may be minimized by following the recommended dosing, the monitoring information, and asking patients about any symptoms of hypocalcaemia.

Concomitant use with cardiac glycosides: Hypercalcaemia of any cause may predispose to digitalis toxicity, monitor serum calcium and cardiac glycoside levels and patients for signs and symptoms of digitalis toxicity.

Severe renal or hepatic disease: Natpar should be used with caution in patients with severe renal or hepatic disease because they have not been evaluated in clinical trials.

Use in young adults: Natpar should be used with caution in young adult patients with open epiphyses.

Tachyphylaxis: the calcium-raising effect of Natpar may diminish over time in some patients. The response of serum calcium concentration to administration of Natpar should be monitored at intervals to detect this and the diagnosis of tachyphylaxis considered.

Urolithiasis: Natpar has not been studied in patients with urolithiasis. Natpar should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.

Adverse Reactions

The most commonly observed adverse events with Natpar treatment were hypercalcaemia, hypocalcaemia, headache, diarrhoea, vomiting, paraesthesia, hypoaesthesia and hypercalciuria.

Very common

(frequency ≥1/10):

Hypercalcaemia, hypocalcaemia, headache, hypoaesthesia, paraesthesia, diarrhoea, nausea, vomiting, arthralgia, and muscle spasms.
Common

(≥1/100 to <1/10):

Hypomagnesaemia, tetany, anxiety, insomnia, somnolence, palpitations, hypertension, cough, upper abdominal pain, muscle twitching, musculoskeletal pain, myalgia, neck pain, pain in extremities, hypercalciuria, pollakiuria, asthenia, chest pain, fatigue, injection site reactions, thirst, anti-PTH antibody positive, blood 25-hydroxycholecalciferol decreased, vitamin D decreased.

 

 

Material code: pi-00658
Date of Preparation of SI: February 2019

Prescribing Information

Body weight (kg) Volume to be injected (mL)
38–41 0.xx
42–45 0.xx
46–49 0.xx
50–53 0.xx
54–57 0.xx
58–61 0.xx
62–65 0.xx
66–69 0.xx
70–73 0.xx
74–77 0.xx
78–81 0.xx
82–85 0.xx
86–89 0.xx
90–93 0.xx

Shire group websites use cookies to maintain an optimal browsing experience. By continuing to view this website, you consent to our use of cookies. Information about our use of cookies is set out below.
Cookies are small text files that a website may place on your computer or mobile device when you visit a site or page. Cookies are useful because they allow the website to recognize your device the next time you visit.

How do Shire websites use cookies?
The cookies we use perform three different functions:

  1. Strictly necessary cookies
    We refer to some cookies as ‘strictly necessary’ cookies because they are essential to enable our visitors to use certain features on our websites. For example, if you enter a username or password to access a secure section of our website, a cookie may be set to keep you from having to enter these details more than once. These cookies do not record personal information that identifies you and are automatically deleted when you close your browser.
  2. Performance cookies
    These cookies are used to analyse how visitors use our website and to monitor our website’s performance. For example, we may check which pages get the most visits and the average time spent on our website. We use this information to improve how our website works. These cookies do not record personal information that identifies you: the information that we receive from them is in the form of aggregated statistics.
    These cookies are stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.
  3. Functionality cookies
    These cookies allow our website to provide a more personal experience and remember any choices you may make. For example, if you visit our website using a mobile device but choose to access our main (non-mobile) site, a cookie may be set to prevent you from being re-directed to our mobile site. These cookies do not record personal information that identifies you. These cookies may be stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

How can I control or delete cookies?
Most browsers are initially set up to automatically accept cookies. You can change the settings on your browser to block cookies or to alert you when cookies are being set on your device. You can also delete cookies stored on your device through your browser. Please refer to your browser instructions or Help screen to learn more about how to adjust or modify your browser settings.
Please note that parts of our websites may not function correctly if you disable the cookies.